FDA Overrules Staff To Broaden Approval Of J&J's Xarelto
The U.S. Food and Drug Administration on Friday approved Johnson & Johnson and Bayer AG's blood thinner Xarelto for treating abnormal heart rhythm after the agency's own staff refused to recommend...To view the full article, register now.
Already a subscriber? Click here to view full article